291 related articles for article (PubMed ID: 27771496)
21. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.
Ansell SM; Ristow KM; Habermann TM; Wiseman GA; Witzig TE
J Clin Oncol; 2002 Sep; 20(18):3885-90. PubMed ID: 12228209
[TBL] [Abstract][Full Text] [Related]
22. Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.
Cassaday RD; Storer BE; Sorror ML; Sandmaier BM; Guthrie KA; Maloney DG; Rajendran JG; Pagel JM; Flowers ME; Green DJ; Rezvani AR; Storb RF; Press OW; Gopal AK
Biol Blood Marrow Transplant; 2015 Feb; 21(2):281-7. PubMed ID: 25445025
[TBL] [Abstract][Full Text] [Related]
23. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
Bethge WA; Faul C; Bornhäuser M; Stuhler G; Beelen DW; Lang P; Stelljes M; Vogel W; Hägele M; Handgretinger R; Kanz L
Blood Cells Mol Dis; 2008; 40(1):13-9. PubMed ID: 17869547
[TBL] [Abstract][Full Text] [Related]
24. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
Tomblyn MR; Ewell M; Bredeson C; Kahl BS; Goodman SA; Horowitz MM; Vose JM; Negrin RS; Laport GG
Biol Blood Marrow Transplant; 2011 Jul; 17(7):1051-7. PubMed ID: 21073974
[TBL] [Abstract][Full Text] [Related]
25. Long-Term Follow-Up of
Puronen CE; Cassaday RD; Stevenson PA; Sandmaier BM; Flowers ME; Green DJ; Maloney DG; Storb RF; Press OW; Gopal AK
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2211-2215. PubMed ID: 30454872
[TBL] [Abstract][Full Text] [Related]
26. Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma.
Shimoni A; Zwas ST; Oksman Y; Hardan I; Shem-Tov N; Rand A; Yerushalmi R; Avigdor A; Ben-Bassat I; Nagler A
Bone Marrow Transplant; 2008 Feb; 41(4):355-61. PubMed ID: 18026153
[TBL] [Abstract][Full Text] [Related]
27. Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: in pursuit of a complete response.
Gisselbrecht C; Vose J; Nademanee A; Gianni AM; Nagler A
Oncologist; 2009; 14 Suppl 2():41-51. PubMed ID: 19819923
[TBL] [Abstract][Full Text] [Related]
28. A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma.
Zinzani PL; Tani M; Fanti S; Stefoni V; Musuraca G; Vitolo U; Perrotti A; Fina M; Derenzini E; Baccarani M
Cancer; 2008 Feb; 112(4):856-62. PubMed ID: 18189293
[TBL] [Abstract][Full Text] [Related]
29. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG
Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369
[TBL] [Abstract][Full Text] [Related]
30. Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
Kang BW; Kim WS; Kim C; Jang G; Lee SS; Choi YH; Lee DH; Kim SW; Kim S; Ryu JS; Huh J; Lee JS; Suh C
Invest New Drugs; 2010 Aug; 28(4):516-22. PubMed ID: 19547918
[TBL] [Abstract][Full Text] [Related]
31. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.
Krishnan A; Nademanee A; Fung HC; Raubitschek AA; Molina A; Yamauchi D; Rodriguez R; Spielberger RT; Falk P; Palmer JM; Forman SJ
J Clin Oncol; 2008 Jan; 26(1):90-5. PubMed ID: 18025438
[TBL] [Abstract][Full Text] [Related]
32. Use of radioimmunotherapy in stem cell transplantation and posttransplantation: focus on yttrium 90 ibritumomab tiuxetan.
Molina A; Krishnan A; Fung H; Flinn IW; Inwards D; Winter JN; Nademanee A
Curr Stem Cell Res Ther; 2007 Sep; 2(3):239-48. PubMed ID: 18220907
[TBL] [Abstract][Full Text] [Related]
33. Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Winter JN; Inwards DJ; Spies S; Wiseman G; Patton D; Erwin W; Rademaker AW; Weitner BB; Williams SF; Tallman MS; Micallef I; Mehta J; Singhal S; Evens AM; Zimmer M; Molina A; White CA; Gordon LI
J Clin Oncol; 2009 Apr; 27(10):1653-9. PubMed ID: 19255322
[TBL] [Abstract][Full Text] [Related]
34. Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma.
Kruger PC; Cooney JP; Turner JH
Cancer Biother Radiopharm; 2012 Nov; 27(9):552-60. PubMed ID: 23062193
[TBL] [Abstract][Full Text] [Related]
35. Successful outcome with reduced-intensity condition regimen followed by allogeneic hematopoietic stem cell transplantation for relapsed or refractory anaplastic large-cell lymphoma.
Fukano R; Mori T; Fujita N; Kobayashi R; Mitsui T; Kato K; Suzuki R; Suzumiya J; Fukuda T; Shindo M; Maseki N; Shimoyama T; Okada K; Inoue M; Inagaki J; Hashii Y; Sato A; Tabuchi K
Int J Hematol; 2019 Dec; 110(6):723-728. PubMed ID: 31620968
[TBL] [Abstract][Full Text] [Related]
36. Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen.
Mei M; Wondergem MJ; Palmer JM; Shimoni A; Hasenkamp J; Tsai NC; Simpson J; Nademanee A; Raubitschek A; Forman SJ; Krishnan AY
Biol Blood Marrow Transplant; 2014 Dec; 20(12):2072-5. PubMed ID: 25079874
[TBL] [Abstract][Full Text] [Related]
37. Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma.
Witzig TE
Drugs Today (Barc); 2004 Feb; 40(2):111-9. PubMed ID: 15045033
[TBL] [Abstract][Full Text] [Related]
38. Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma.
Fruchart C; Tilly H; Morschhauser F; Ghesquières H; Bouteloup M; Fermé C; Van Den Neste E; Bordessoule D; Bouabdallah R; Delmer A; Casasnovas RO; Ysebaert L; Ciappuccini R; Briere J; Gisselbrecht C
Biol Blood Marrow Transplant; 2014 Dec; 20(12):1905-11. PubMed ID: 25072780
[TBL] [Abstract][Full Text] [Related]
39. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.
Morschhauser F; Radford J; Van Hoof A; Vitolo U; Soubeyran P; Tilly H; Huijgens PC; Kolstad A; d'Amore F; Gonzalez Diaz M; Petrini M; Sebban C; Zinzani PL; van Oers MH; van Putten W; Bischof-Delaloye A; Rohatiner A; Salles G; Kuhlmann J; Hagenbeek A
J Clin Oncol; 2008 Nov; 26(32):5156-64. PubMed ID: 18854568
[TBL] [Abstract][Full Text] [Related]
40. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial.
Morschhauser F; Radford J; Van Hoof A; Botto B; Rohatiner AZ; Salles G; Soubeyran P; Tilly H; Bischof-Delaloye A; van Putten WL; Kylstra JW; Hagenbeek A
J Clin Oncol; 2013 Jun; 31(16):1977-83. PubMed ID: 23547079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
